Impact News +++ ABIONYX Pharma Is Launching a Capital Increase With Cancellation of Preferential Subscription Rights in... (Business Wire) +++ ABIONYX Aktie -4,27%

TUHURA Aktie

>TUHURA Aktienkurs

0.79 EUR -3.7% (Tradegate)

Ask: 0.79 EUR / 6305 Stück

Bid: 0.76 EUR / 6611 Stück

Tagesumsatz: 2166 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

TUHURA Aktie über LYNX handeln

Intraday

1 Jahr

>TUHURA Performance

1 Woche: -24,0%

1 Monat: -54,9%

3 Monate: -62,2%

6 Monate: -64,4%

1 Jahr: 0%

laufendes Jahr: 0%

>TUHURA Aktie

Name:

TUHURA BIOSCIENCES INC.

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US8989201038 / A3EWMJ

Symbol/ Ticker:

PL3 (Frankfurt) / HURA (NASDAQ)

Kürzel:

FRA:PL3, ETR:PL3, PL3:GR, NASDAQ:HURA

Index:

Webseite:

https://tuhurabio.com/

Profil:

TuHURA Biosciences, Inc. is a Phase III registrati..
>Volltext..

Marktkapitalisierung:

45.19 Mio. EUR

Unternehmenswert:

43.62 Mio. EUR

Umsatz:

EBITDA:

-21.59 Mio. EUR

Nettogewinn:

-24.95 Mio. EUR

Gewinn je Aktie:

-0.55 EUR

Schulden:

0.49 Mio. EUR

Liquide Mittel:

2.3 Mio. EUR

Operativer Cashflow:

-21.02 Mio. EUR

Bargeldquote:

0.31

Umsatzwachstum:

Gewinnwachstum:

-132.57%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

TUHURA

Letzte Datenerhebung:

16.12.25

>TUHURA Kennzahlen

Aktien/ Unternehmen:

Aktien: 51.26 Mio. St.

Frei handelbar: 70.64%

Leerverk. Aktien: 4.73%

Rückkaufquote: -30.1%

Mitarbeiter: 19

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 728.17%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 3.23

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -110.91%

Eigenkaprendite: -418.06%

>TUHURA Peer Group

Es sind 599 Aktien bekannt.

>TUHURA Chart & Kurs - NASDAQ

>TUHURA News

15.12.25 - 13:54	TuHURA Biosciences Announces its Release of Kintara′s Contingent Value Right (CVR) as Kintara′s REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone (PR Newswire)
	Milestone Triggers Release of Shares to Kintara Contingent Value Right (CVR) Holders TAMPA, Fla., Dec. 15, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to......

11.12.25 - 13:33	TuHURA Biosciences Provides Corporate Update Following Recent Financing (PR Newswire)
	Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA)......

09.12.25 - 15:51	TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering (PR Newswire)
	TAMPA, Fla., Dec. 9, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for......

08.12.25 - 13:54	TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition (PR Newswire)
	Oral Presentation highlighted new scientific evidence that DOR is expressed on tumor-associated Myeloid-Derived Suppressor Cells (MDSCs), and its inhibition decreases immune suppressing capabilities of MDSCs by downregulating expression of multiple genes associated with MDSC induced......

14.11.25 - 13:33	TuHURA Biosciences GAAP EPS of -$0.14 beats by $0.01 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.11.25 - 13:03	TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC) is underway, conducted under Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug......

03.11.25 - 15:48	TuHURA Biosciences: Aktie legt nach Annahme von Krebsforschung für wichtige Konferenz zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.11.25 - 15:03	TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition (PR Newswire)
	Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and that DOR inhibition reprograms multiple mechanisms of MDSC- induced immunosuppression representing a new target in overcoming acquired resistance to cancer......

20.08.25 - 14:06	TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference (PR Newswire)
	TAMPA, Fla., Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright......

15.08.25 - 04:36	TuHURA R&D Jumps 75% in Q2 (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

14.08.25 - 22:18	TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (PR Newswire)
	Completed the acquisition of Kineta, Inc. and its VISTA inhibiting monoclonal antibody (mAb), now named "TBS-2025;" planning to initiate a Phase 2 trial in relapsed/refractory NPM1-mutated Acute Myeloid Leukemia (AML) in combination with a menin inhibitor in 2H 2025 Initiated a Phase 3......

01.07.25 - 14:51	TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes (PR Newswire)
	TAMPA, Fla., July 1, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the Company has been added to the Russell......

30.06.25 - 14:54	TuHURA Biosciences Completes Acquisition of Kineta (PR Newswire)
	Acquisition adds Phase 2 ready novel VISTA inhibiting monoclonal antibody (mAb) to TuHURA's late-stage immuno-oncology pipeline TuHURA planning to initiate a Phase 2 randomized trial involving VISTA inhibiting antibody in 2nd Half 2025 Completion of the acquisition unlocks the fourth......

24.06.25 - 14:01	TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma (PR Newswire)
	Phase 3 trial being conducted under a Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Primary endpoint of Overall Response Rate (ORR) qualifies for accelerated approval process Key secondary endpoint of Progression Free Survival (PFS) may satisfy......

23.06.25 - 23:24	TuHURA Biosciences and Kineta stockholders approve proposed deal (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.06.25 - 23:02	TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals (PR Newswire)
	TAMPA, Fla. and SEATTLE, June 23, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced with Kineta, Inc. (OTC Pink:KANT)......

10.06.25 - 00:45	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders (PR Newswire)
	NEW YORK, June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s......

09.06.25 - 14:03	FDA Removes Partial Clinical Hold on TuHURA Biosciences′ Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma (PR Newswire)
	Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as first-line treatment for advanced and metastatic Merkel cell carcinoma (MCC), conducted under Special Protocol Assessment (SPA) Agreement with U.S.......

03.06.25 - 16:01	TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy (PR Newswire)
	Secures $12.5 million of commitments in a private offering Secures an additional $3.0 million through payment of cash exercise price of warrants Funding provides capital for: Initiation of planned Phase 3 accelerated approval trial of IFx-2.0 targeting 40% enrollment by 2-2025 year end......

02.06.25 - 14:06	TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting (PR Newswire)
	Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Der Mensch ward zum Tun und nicht zum Vernünfteln erschaffen. Aber eben deswegen, weil er nicht dazu erschaffen ward, hängt er diesem mehr als jenem nach. - Gotthold Ephraim Lessing

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram